Sadal Emine BENZER, SÜLEYMAN DEMİR, Gülay BİLİR, Yılmaz Eda AKÇAY, İ. Ebru ARABACI

Klasik Hodgkin lenfomalarda EBV-LMP 1 ekspresyonunun histopatolojik subtiplere göre dağılımı

Epstein-Barr virüs, klasik Hodgkin lenfomaların patogenezinde yer almaktadır. Epstein-Barr virüs latent membran prote-in-1 (EBV-LMP1) Hodgkin ve Reed Stemberg (HRS) hücrelerinde sıklıkla eksprese edilmektedir. Bu çalışmada klasik Hodgkin lenfoma olgularında immünhistokimyasal olarak EBV-LMP1 ekspresyonu ve histopatolojik subtiplere göre dağılımı araştırılmıştır. Ankara Onkoloji Hastanesi patoloji bölümünde 1998-2004 yılları arasında klasik Hodgkin lenfoma tanısı alan ve çalışma için yeterli doku örnekleri mevcut olan toplam 37 olgu çalışma grubunu oluşturmaktadır. İmmünhistokimyasal olarak anti-EBV-LMP1 antikoru ile boyama yapılmıştır. Otuzyedi klasik Hodgkin lenfoma olgusunun 19'unda (%51,35) EBV-LMP1 ekspresyonu izlenmiştir. Onüç mikst selüler subtipin 11'inde (%84,6), 14 nodüler sklerozan subtipin üçünde (%21,4), altı lenfositten yoksun subtipin beşinde (%83,3) EBV-LMP1 ile HRS hücrelerinde boyanma olmuştur. Dört lenfositten zengin subtipin hiçbirinde boyanma izlenmemiştir.EBV-LMP1'in klasik Hodgkin lenfoma olgularında ekspresyonu, EBV enfeksiyonunun patogenezde rolü olduğunu desteklemektedir. Histopatolojik subtiplerden en yüksek oranda ekspresyon mikst selüler tipte, en düşük oranda ekspresyon ise lenfositten zengin tipte izlenmiştir.EBV enfeksiyonu ile ilişkili olmayan olgularda patogenezde başka ajanların araştırılması gerekmektedir.

Anahtar Kelimeler:

Lenfom, Antijenler, viral, Herpesvirüs 4, insan, Hodgkin hastalığı

Distribution of EBV-LMP 1 expression according to histopathological subtypes of classical Hodgkin's lymphomas

Epstein -Barr virus plays role in the pathogenesis of classical Hodgkin's lymphomas. Epstein Barr virus latent membrane protein-1 ( EBV-LMP 1 ) is usually expressed in Hodgkin and Reed Stern berg ( HRS ) cells. In this study, the immunohistochemical expression of EBV-LMP 1 in classical Hodgkin's lympoma cases and its distribution according to histopathological subtypes were investigated.In Ankara Oncology Hospital, Department of Pathology, 37 cases; diagnosed as Hodgkin's lymphoma between 1998-2004 with adequate tissue samples to study, were included in this study group. Immunohistochemically, staining with anti EBV-LMP'1 antibody was applied.In 19 of 37 classical Hodgkin's lymphoma cases (51,35%) EBV-LMP 1 expression was observed. In 11 of 13 mixt cellularity subtype (84,6%), three of 14 nodular sclerosis subtype (21,4%), five of six lymphocyte depleted subtyf. (83,3%) EBV-LMP1 expression was seen in HRS cells. No expression was observed in all of four lymphocyte rk subtype. In classical Hodgkin's lymphoma cases, the expression of EBV-LMP1 supports that EBV infection plays a role pathogenesis. Among the histopathological subtypes highest expression ratio was observed in mixed cellularity typ lowest ratio was observed in lymphocyte rich type.Other agents must be researched in the pathogenesis of the cases which are not associated with EBV infection.

Keywords:

Lymphoma, Antigens, Viral, Herpesvirus 4, Human, Hodgkin Disease,

PDF

___

1. Herling M, Rassidakis GZ, Medeiros Lj, et al. Expression of Epstein-Barr Virus Latent Membrane protein-1 in Hodgkin and Reed-Sternberg Cells of classical Hodgkin's Lymphoma : Associations with presenting features, Serum Interleukin 10 Levels and Clinical Outcome .Clin Cancer Res., 9:2114-2120, 2003.
2. Vasef MA, Ubaidat MA, Khalid. Hs, et al. Association between Epstein-Barr Virus and Classic Hodgkin Lymphoma in Jordan- A comparative study with Epstein-Barr Virus-associated Hodgkin Lymphoma in North America. South Med. J., 97(3):273-277, 2004.
3. Dukers DF, Jaopars LH, Vos W, et al. Quantitative immunohistochemical analysis of cytokine profiles in Epstein-Barr virus-positive and negative cases of Hodgkin's disease. J. Pathol, 19:143-149,2000.
4. Gulley ML, Glaser SL, Craig FE, et al. Guidelines for interpreting EBER in Situ Hybridization and LMP immunohistochemical Test's for Detecting Epstein Barr Virus in Hodgkin Lymphoma. Hematopathology, 117:259-267, 2002.
5. Lucas KG, Saizman D, Garcia A, Sun Q. Adoptive Immunotherapy with Allogenic Epstein-Barr Virus (EBV)-specific cytotoxic T-Lymphpcytes for recurrent EBV-positive Hodgkin Disease. Cancer, 100(9): 1892-1901, 2004.
6. Karnık S, Srınıvasan B, Naır S. Hodgkin's Lymphoma: Immunohistochemical features and its association with EBV LMP-1. Experience from a South Indian hospital. Pathology, 35:207-211, 2003.
7. Jarret RF, Krajewski AS, Angus B, et al. The Scotland and Newcastle epitemiological study of Hodgkin's Disease: impact of histopathological review and EBV status on incidence estimates. J Clin pathol., 56:811-816, 2003.
8. Krugmann J, Tzankov A, Gschwendtner A, et al. Longer failure-free survival interval of Epstein-Barr Virus-associated classical Hodgkin's Lymphoma: A single-instituation study. Mod Pathol, 16:566-573, 2003.
9. Meij P, Vervoort M, Bloemena E, et al. Antibody Responses to Epstein-Barr Virus-encoded Latent Membran protein-1 (LMP-1) and expression of LMP in Juvenile Hodgkin's Disease. J Med. Virol., 68:379-377, 2002.
10. Nerurkar AY, Vijoyan P, Srinivas V, et al. Discrepancies in Eptein-Barr virus association at presentation and relapse of classical Hodgkin's disease: impact on pathogenenis. Ann Oncol., 11: 475-478, 2000.
11. SwerdlowAJ. Epidemiology of Hodgkin's disease and non-Hodgkin's lymphoma. Eur J NucMed Mol Imag., 30: S(1), 1-11, 2003.
12. Durdov MG, Razumovic JJ, Capkun V, Murray P. Assesment of the prognostic impact of the Epstein-Barr Virus-encoded latent membrane protein-1 expression in Hodgkin's disease. Br J Cancer, 84(9): 1227-1234, 2001.